Actelion announces first quarter 2012 financial results
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Actelion announces first quarter 2012 financial results
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Product sales of CHF 415.8 million, down 4% in local currencies - 2012 Product
sales guidance upgraded to low single digit decrease - Core Earnings of CHF
107.6 million, down 9 % in local currencies - 2012 Flat Core Earnings Guidance
reiterated - Macitentan results in morbidity/mortality PAH study expected in the
next few weeks
ALLSCHWIL/BASEL, SWITZERLAND - 19 April 2012 - Actelion Ltd (SIX: ATLN) today
announced its financial results for the first quarter 2012.
In CHF Million | Results | Results | % Variance | % Variance
(except for per share data) | Q1 2012 | Q1 2011 | In CHF | In LC
------------------------------+---------+---------+------------+------------
Total net revenues | 417.5 | 528.2 | (21%) | (18%)
------------------------------+---------+---------+------------+------------
Product sales | 415.8 | 450.1 | (8%) | (4%)
------------------------------+---------+---------+------------+------------
US GAAP EBIT | 67.1 | 164.7 | (59%) | (54%)
------------------------------+---------+---------+------------+------------
Core earnings | 107.6 | 127.9 | (16%) | (9%)
------------------------------+---------+---------+------------+------------
US GAAP EPS (fully diluted) | 0.38 | 1.20 | (68%) | (63%)
As of 31 March 2012, Actelion had cash and cash equivalents of CHF 1.3 billion
(includes restricted cash of CHF 365 million). In addition, Actelion holds 13.9
million treasury shares.
Jean-Paul Clozel, M.D. and Chief Executive Officer of Actelion commented: "As
expected, the market place remains very challenging, mostly due to changes in
the competitive landscape in the United States and strong pricing pressures in
certain markets. In that context, our product sales performance is acceptable.
Jean-Paul Clozel continued: "In this difficult environment, Actelion maintained
its strong global leadership in the endothelin receptor antagonist market. We
hope to build on this position of strength with SERAPHIN, a morbidity/mortality
study evaluating our second-generation endothelin receptor antagonist,
macitentan. I expect study results to become available in the next few weeks."
Andrew J. Oakley, Chief Financial Officer of Actelion commented: "In the first
quarter of 2012, Actelion's overall performance reflects the dynamics of the
market place, including the continued strength of the Swiss Franc."
Initially, Actelion expected 2012 product sales (in local currencies) to
decrease in the low-to mid-single digit range. In the first quarter 2012, while
overall pricing pressure has remained very high, the US pricing environment
improved slightly during the first quarter. Moving forward, Tracleer(®) pricing
in Japan was left unchanged by the Japanese authorities.
Andrew Oakley continued: "Unforeseen events excluded, Actelion can now provide
an improved product sales forecast. The decrease in local currencies is now
expected to be in the low-single digit range. Actelion remains on track to meet
its previously issued guidance of flat 2012 core earnings."
Revenue performance
Product sales for the first quarter of 2012 were CHF 415.8 million (Q1 2011 CHF
450.1 million), a decrease of 4 % in local currencies with 37 % of sales coming
from the United States, 41 % from Europe, 11 % from Japan and 11 % from the rest
of the world.
First quarter 2012 sales of Tracleer (bosentan) amounted to CHF 363.7 million
compared to CHF 402.8 million for the same period in 2011. This represents a
decrease of 6 % in local currencies and a decrease of 1% in units shipped.
During the first quarter 2012, Ventavis(®) (iloprost) had sales in the United
States of CHF 27.7 million compared to CHF 28.0 million in the first quarter
2011. In local currencies, this represents an increase of 1 %, with unit decline
compensated by price.
Sales of Zavesca(®) (miglustat), for the first quarter of 2012 amounted to CHF
18.6 million compared to CHF 16.5 million during the same period last year. This
represents an increase of 19 % in local currencies driven predominantly by
strong patient demand in Niemann Pick Type-C indication (outside the US) as well
as a positive US pricing impact.
Actelion's fourth product in the US is Veletri(®) (epoprostenol for injection),
a parenteral prostacyclin formulation providing the efficacy of epoprostenol
with an increased stability at room temperature. Sales of this product for the
first quarter of 2012 amounted to CHF 5.3 million. Registration in Japan and
Europe with the second generation formulation is ongoing.
Contract revenues for the first quarter of 2012 amounted to CHF 1.6 million.
Contract revenues for the first quarter of 2011 amounted to CHF 78.1 million,
with the majority of this amount (CHF 76.5 million) stemming from the final
recognition of the remaining deferred revenue from the ongoing orexin
collaboration with GlaxoSmithKline.
Operating expenses
Total operating expenses for the first quarter 2012 were CHF 350.3 million
compared to CHF 363.6 million for the first quarter of 2011, a decrease of 4 %.
Research and Development (R&D) expenses in the first quarter of 2012 were up 8 %
to CHF 129.9 million (Q1 2011: CHF 120.7 million). This increase was entirely
driven by a USD 10 million milestone payment to Auxilium Pharmaceuticals,
related to the collaboration the two companies announced in February 2012 for
XIAFLEX in Canada, Australia, Brazil and Mexico.
Non-GAAP R&D expenses for the same period, which excludes stock-based
compensation expense, amortization and depreciation as well as the payment to
Auxilium, were basically flat at CHF 105.4 million compared to CHF 105.8 million
in the first quarter 2011.
Selling, General and Administrative expenses (SG&A) for the first quarter of
2012 were CHF 161.9 million (Q1 2011: CHF 181.4 million), representing a
decrease of 11 %.
Non-GAAP SG&A expenses for the first quarter of 2012, which excludes stock-based
compensation expense, amortization and depreciation, were CHF 154.1 million
compared to CHF 165.1 million in the first quarter 2011, a decrease of 4 % on a
local currency basis or 12 % excluding the effect of doubtful debt provisions in
both comparative periods.
Operating income
Operating income for the first quarter 2012 was CHF 67.1 million compared to CHF
164.7 million for the same period in 2011, a decrease of 59%. In local
currencies operating income decreased by 54 %.
In order to better compare the company's underlying performance, Actelion
reports core earnings as product sales minus cash operating expenses, as well as
other items that may distort comparison.
For the first quarter of 2012, core earnings amounted to CHF 107.6 million
compared to CHF 127.9 million during the first quarter of 2011. This represents
a decrease of 9 % in local currencies.
Net income
Net income for the first quarter 2012 amounted to CHF 45.1 million (Q1 2011: CHF
146.3 million). This represents a decrease of 69 % in Swiss Franc terms or 64 %
in local currencies.
Net income for the period includes interest income of CHF 0.5 million, interest
expense of CHF 0.4 million, interest expense on the litigation provision of CHF
9.4 million, interest expense on the Swiss Franc bond of CHF 3.0 million,
impairment of financial assets of CHF 0.3 million related to Greek bonds, and
other financial expense of CHF 0.9 million related to hedging and valuation
gains and losses.
Income tax expense for the first quarter amounts to CHF 8.6 million which
translates into a tax rate of 16 %.
US GAAP earnings per share on a fully diluted basis in the first quarter 2012
decreased by 68 % compared to the same period a year ago to CHF 0.38 whilst Core
earnings per share decreased by 31 % to CHF 0.66.
Clinical Development update
Actelion provided a full clinical pipeline update in the Annual Report,
published 14 February 2012. Since then, the company has made the following
changes:
Actelion is re-directing its development efforts in the anti-inflammatory area,
focusing on a potent follow-up CRTH2 antagonist currently in Phase I clinical
development. Two recently concluded studies with the first orally-active CRTH2
antagonist, setipiprant, in asthma (Phase IIb) and seasonal allergic rhinitis
(Phase III profiling) did not confirm efficacy findings made in earlier
studies. Accordingly, clinical development with this well-tolerated agent in
these indications is being discontinued.
In Q1 2012, Actelion also concluded the evaluation of a cardiovascular compound
in a proof-of-concept study in essential hypertension. The desired target
profile was not achieved. Development of this compound in such cardiovascular
indications as essential hypertension or stable angina will not be further
pursued.
NOTE TO THE SHAREHOLDERS:
The Annual General Meeting of Shareholders to approve the Business Report of the
year ending 31 December 2011 will be held on 4 May 2012.
In order to attend and vote at the Annual General Meeting of Shareholders,
shareholders must be registered in the Company's shareholders register by 25
April 2012 at the latest. For information on how to register shares, please
visit the company's website at http://www.actelion.com/en/investors/first-time-
investor/how-to-register-shares.page?
Upcoming events
* Actelion Annual General Meeting - 4 May 2012
* H1 2012 financial results - 19 July 2012
* 9M 2012 financial results - 18 October 2012
###
For Documentation Purposes
Full Financial Statement:
The full financial statement for the first quarter of 2012 can be found as a PDF
attached to the media release. It is also available on www.actelion.com in the
Investor section
http://www.actelion.com/en/investors/financial-information/finance-
archive/index.page?
Non-GAAP to US GAAP reconciliation for Q1 2011
In CHF Million | Q1 2012 | Q1 2011
--------------------------------+---------+---------
Core Earnings | 107.6 | 127.9
--------------------------------+---------+---------
Contract revenues | 1.6 | 78.1
--------------------------------+---------+---------
Stock option expenses | (12.6) | (20.4)
--------------------------------+---------+---------
Amortization and depreciation | (20.4) | (20.9)
--------------------------------+---------+---------
Auxilium milestone payment | (9.1) | -
--------------------------------+---------+---------
US GAAP EBIT | 67.1 | 164.7
| |
Notes to the editor:
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,500 employees focus on
the discovery, development and marketing of innovative drugs for significant
unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange
(ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market
Index SMI®).
For further information please contact:
Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
Conference Call Information
Actelion Ltd will announce the first quarter 2012 financial results on Thursday,
19 April 2012, at 07.00 hrs CEST / 06.00 hrs BST / 01.00 a.m. EST. An investor
conference call & webcast will be held at 14.00 hrs, CEST to discuss the
results.
Date/Time:
19 April 2012 14.00 hrs Basel (CEST)
13.00 hrs UK (BST)
08.00 a.m US (EST)
Conference Call Connect #:
Dial-in participants should start calling the number below 10-15 minutes before
the conference is due to start.
Dial: Europe: +41 (0)44 580 00 74
UK: +44 (0)203 367 94 53
US: +1 866 907 59 23
Participant mode:
Listen-Only with possibility to open individual lines during Q&A session.
Participants will be asked for their Name and Company.
Webcast Access:
Webcast participants should visit the Actelion website http://www.actelion.com
10-15 minutes before the conference is due to start.
Participant mode:
Listen-Only
Webcast Replay:
The archived Investor Webcast will be available for replay through
http://www.actelion.com
approximately 60 minutes after the call has ended.
Webcast:
http://view-w.tv/p/120-121-11125/en
Press Release PDF:
http://hugin.info/131801/R/1603781/507207.pdf
Financial Statement:
http://hugin.info/131801/R/1603781/507213.pdf
Financial Fact Sheet:
http://hugin.info/131801/R/1603781/507212.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
[HUG#1603781]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 19.04.2012 - 01:01 Uhr
Sprache: Deutsch
News-ID 1104738
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Allschwil
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 113 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion announces first quarter 2012 financial results
"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
